Neogenix gets additional QTDP grant
The grant which is awarded under the Qualifying Therapeutic Discovery Project Program (QTDP) to Neogenix is totaled up to $733,437.74. The company’s NPC-1C (Ensituximab) monoclonal antibody is currently
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
The trial will evaluate the efficacy of Erbitux in combination with cisplatin and capecitabine chemotherapies as a first line treatment for patients with advanced/metastatic gastric adenocarcinoma, including gastroesophageal